Welcome to our dedicated page for Corvus Pharmaceuticals news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a pioneering clinical-stage biopharmaceutical company focused on the development of novel immunotherapies to treat a broad spectrum of cancers and immune diseases. The company's core innovation is the selective inhibition of interleukin-2-inducible T cell kinase (ITK), which plays a crucial role in T cell and natural killer (NK) cell immune functions. Corvus' lead investigational product, soquelitinib (formerly CPI-818), has shown promise in optimizing T cell differentiation and enhancing immune responses against tumors, as well as in the management of autoimmune diseases.
Corvus is advancing soquelitinib through a Phase 3 registrational trial for relapsed peripheral T cell lymphoma (PTCL), an aggressive and typically treatment-resistant form of non-Hodgkin’s lymphoma. The company’s focus on ITK inhibition offers a new therapeutic approach, given the lack of FDA-approved treatments for relapsed PTCL. Soquelitinib has demonstrated the ability to prevent T cell exhaustion and promote the generation of cytotoxic killer T cells, critical in cancer therapy.
In addition, Corvus is investigating soquelitinib for other immune-mediated conditions, including atopic dermatitis. The company recently initiated a randomized, double-blind Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis, aiming to provide an oral treatment alternative to current injectable biologics.
Other promising candidates in Corvus' pipeline include ciforadenant, an adenosine A2A receptor inhibitor that disables tumors' immune evasion mechanisms, and mupadolimab, a monoclonal antibody targeting CD73. These candidates are being studied for their efficacy in combination therapies for various cancers, including head and neck cancers and non-small cell lung cancer.
Financially, Corvus maintains a strong position, having raised significant capital through direct offerings to support its clinical trials and operational needs. With cash reserves projected to fund operations into late 2025, Corvus is well-positioned to achieve substantial milestones in its clinical programs. The company continues to foster critical partnerships, including collaborations with Angel Pharmaceuticals for the Chinese market.
Latest news highlights Corvus' progress in clinical trials and strategic financing moves, underscoring its commitment to bringing innovative immunotherapies to patients in need. For more information, visit the Corvus Pharmaceuticals website.
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker CRVS, has announced that it will participate in the Jefferies Global Health Conference in New York from June 5-7, 2024. The company's CEO, Richard A. Miller, and Chief Business Officer, Jeffrey Arcara, will present a corporate overview and conduct one-on-one meetings with investors. The presentation is scheduled for June 5 at 3:00 pm ET and will be webcast live, with the recording available for 90 days on the company's investor relations webpage.
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, reported strong progress in advancing soquelitinib for PTCL and generating early data for atopic dermatitis. Recent financing provided runway for expected clinical readouts in 2024-2025. Positive Phase 1 trial results for ciforadenant in renal cell cancer. Corvus also collaborates with Kidney Cancer Research Consortium and Angel Pharmaceuticals. Financially, Corvus reported cash, cash equivalents, and marketable securities of $22.1 million as of March 31, 2024, with expected full year 2024 net cash used in operating activities between $24-27 million.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) will provide a business update and report first quarter 2024 financial results on May 6, 2024. The company will host a conference call and webcast at 4:30 pm ET / 1:30 pm PT. Investors can access the call through dial-in numbers or the webcast link. A replay will be available on the company's website.
Corvus Pharmaceuticals has announced a $30.6 million registered direct offering to raise gross proceeds through the sale of common stock and warrants. The offering includes participation from various healthcare investors and existing investors, with the company's CEO also joining. The offering is expected to close on May 6, 2024.
FAQ
What is the current stock price of Corvus Pharmaceuticals (CRVS)?
What is the market cap of Corvus Pharmaceuticals (CRVS)?
What is Corvus Pharmaceuticals' lead product candidate?
What conditions is Corvus Pharmaceuticals targeting with soquelitinib?
What is the significance of ITK inhibition in Corvus Pharmaceuticals' research?
What other products are in Corvus Pharmaceuticals' pipeline?
What recent financial developments have supported Corvus Pharmaceuticals' research?
What is the background of Corvus Pharmaceuticals?
What partnerships does Corvus Pharmaceuticals have?
How is Corvus Pharmaceuticals addressing the unmet needs in relapsed PTCL?
How is soquelitinib being evaluated for atopic dermatitis?
What makes mupadolimab unique in Corvus Pharmaceuticals' research?
